Zanidatamab regimens improve survival for gastroesophageal cancer
First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...
First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...
A 63-year-old patient with HER2-positive metastatic gastroesophageal junction adenocarcinoma achieved 23 months of progression-free survival on second-line trastuzumab deruxtecan f...
Salivary gland cancer is rare, and there are no standard treatments for advanced-stage disease. Recent research supports the use of HER2-targeted therapy for patients with metastat...
SHANGHAI, Oct. 25, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that...
HONG KONG, Oct. 25, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter, registr...
Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line P...
The companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a hig...
HONG KONG, Nov. 4, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanc...
A pancreatic cancer drug is now available in Greece, offering an option for patients with advanced disease.
64 research findings have been accepted, including three Proffered Paper presentations and three Rapid Oral presentations, spanning more than ten areas of oncology and supportive c...
Wilserdly’s U.S. approval is seen by analysts as a “key first step” in an important launch for Roche, which has claimed the drug could become its top-selling product.
TUESDAY, Nov. 17, 2026 — People with advanced breast cancer that has stopped responding to hormone therapy now have a new pill-based treatment option. The U.S. Food and Drug Admini...
TUESDAY, Nov. 17, 2026 — People with advanced breast cancer that has stopped responding to hormone therapy now have a new pill-based treatment option. The U.S. Food and Drug Admini...
The FDA approved lirafugratinib — a kinase inhibitor — for adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma.The indication for lirafug...
Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed acr...
Korean drugmaker HLB has resubmitted its application for U.S. approval of a combination therapy for advanced liver cancer, renewing its push to bring the target treatment to market...
Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of death (HR 0.69; 95% CI 0.54–0.89;...
CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares.
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.